Article Text

Download PDFPDF
Efficacy of anakinra, an IL1 receptor antagonist, in refractory Sweet syndrome
  1. A Delluc1,
  2. N Limal1,
  3. X Puéchal2,
  4. C Francès1,
  5. J C Piette1,
  6. P Cacoub1
  1. 1
    Université Pierre et Marie Curie Paris 6, CNRS, UMR 7087, Paris, France; AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, France
  2. 2
    Service de Rhumatologie, Centre Hospitalier du Mans, France
  1. Professor P Cacoub, AP-HP, Hôpital Pitié-Salpêtrière, Service de Médecine Interne, Paris, F-75013 France; patrice.cacoub{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Sweet syndrome (SS) is a neutrophilic dermatosis characterised by fever, neutrophilia, tender erythematous skin lesions and a diffuse infiltrate consisting predominantly of mature neutrophils that are typically located in the upper dermis.1 The scarcity of the disease does not allow evaluation of drug responses in randomised controlled trials. This report describes for the first time the dramatic efficacy of a treatment with the interleukin 1 (IL-1) receptor antagonist in a patient presenting with refractory SS.


A 55-year-old woman had, since 1998, recurrent fever, pulmonary involvement (alveolar lung condensations), elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) without evidence of an infectious or inflammatory disease. Skin lesions of the right flank were occasionally …

View Full Text


  • Competing interests: None declared